Shares of Gaxos.ai Inc. (GXAI) experienced a dramatic surge on Tuesday, climbing approximately 57% to $1.87 by midday, following the company's announcement that Amazon Web Services (AWS) is increasing its financial commitment to the development of Gaxos Labs' artificial intelligence-powered sales-coaching platform. Trading volume exploded to over 93 million shares, far exceeding the nano-cap stock's typical activity, as investors seized on the news as a significant endorsement from a major cloud provider.
The stock reached an intraday high of $2.30 before settling, reflecting a gain of 68 cents. The move came amid a broader resurgence of enthusiasm for AI-related stocks, fueled by renewed investor interest in artificial intelligence and reports of increased infrastructure spending by major technology firms. Global equity markets received a boost from this renewed AI momentum, according to Reuters, providing a supportive backdrop for Gaxos's announcement.
Gaxos revealed that it is collaborating with AWS and Caylent, an AWS Premier Tier Services Partner, to build a real-time sales-coaching platform for enterprise clients. Planned features include live call transcription, automated coaching intelligence, and post-call analytics. The company's CEO, Vadim Mats, characterized the AWS funding as a "major validation event," stating that the collaboration "materially advances our roadmap and enhances our ability to pursue large-scale commercial opportunities."
However, the company did not disclose the size of the AWS investment, the expected launch date, or any new revenue commitments. As a result, traders focused on the symbolic significance of the partnership rather than concrete financial details. This lack of specificity leaves the announcement open to interpretation, with the market betting on future potential rather than current performance.
Gaxos is actively pivoting away from its core gaming and consumer AI focus to target larger sectors such as healthcare, defense, productivity, and enterprise software. In the sales technology space, this positions the company against established players like Salesforce and HubSpot, both of which already offer customer management and sales workflow tools with integrated AI features. Notably, shares of Salesforce and HubSpot were both trading lower on Tuesday, suggesting that investors see Gaxos as a potential disruptive force in the market.
Despite the stock's rally, the company's recent financial results paint a mixed picture. Gaxos reported first-quarter revenue of $1.81 million, a significant jump from $23,732 in the same period last year, driven by RNK Health administrative services and AI subscriptions. However, the net loss widened to $2.47 million, and advertising and marketing expenses soared to $2.77 million. The company ended the quarter with $1.51 million in cash, $10.20 million in short-term investments, and working capital of $11.59 million, providing a liquidity cushion. Cash used in operations totaled $2.49 million for the quarter.
Earlier this year, Gaxos raised approximately $5.3 million in net proceeds through an at-the-market equity offering, selling 3.10 million shares. An amended filing on May 18 corrected the outstanding share count to 10.22 million as of May 13. Analyst Lisa Thompson of Zacks Small Cap Research, which has a paid relationship with Gaxos, noted on May 20 that the company "continues to beat on the top line" and raised her 2026 revenue estimate to $8.7 million. She cautioned, however, that initial customers may incur losses due to high acquisition costs, though "repeat orders add to profits."
The significant move in GXAI shares is largely driven by optimism surrounding the AWS partnership, but the company's fundamentals remain a concern. With widening losses, high marketing costs, and no concrete details on the deal's financial impact, the rally is built more on hope than hard numbers. Investors will be watching closely for signs that the AWS backing translates into real enterprise clients and sustainable revenue growth. If the company fails to convert this validation into commercial traction, the stock could face a sharp reversal.
